Cargando…
Plasmodium vivax pre-erythrocytic vaccines
An estimated 229 million cases of malaria occurred worldwide in 2019. Both, Plasmodium falciparum and P. vivax are responsible for most of the malaria disease burden in the world. Despite difficulties in obtaining an accurate number, the global estimates of cases in 2019 are approximately 229 millio...
Autor principal: | Reyes-Sandoval, Arturo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606753/ https://www.ncbi.nlm.nih.gov/pubmed/34166786 http://dx.doi.org/10.1016/j.parint.2021.102411 |
Ejemplares similares
-
Preliminary characterization of Plasmodium vivax sporozoite antigens as pre-erythrocytic vaccine candidates
por: Nicholas, Justin, et al.
Publicado: (2023) -
Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine for Preventing Relapses
por: White, Michael, et al.
Publicado: (2017) -
Plasmodium vivax malaria vaccines: Why are we where we are?
por: Reyes-Sandoval, Arturo, et al.
Publicado: (2013) -
Development of novel vaccine candidates and challenge models for Plasmodium vivax
por: Alves, Eduardo, et al.
Publicado: (2014) -
Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein
por: Atcheson, Erwan, et al.
Publicado: (2020)